Nuo Therapeutics, Inc. announced that it has received $1.035 million in funding

Nuo Therapeutics, Inc. is a regenerative therapies company. The Company is focused on developing and marketing products for chronic wound care primarily within the United States. The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. Its flagship product, Aurix, is a biodynamic hematogel that uses a patient’s own platelets and plasma as a catalyst for healing. The Company’s commercial offering consists of point of care technology for the safe and effective separation of autologous blood to produce a platelet-based therapy for the chronic wound care market. This offering is known as Aurix (the Aurix System), which produces a platelet rich plasma (PRP) gel at the point of care using the patient’s own platelets and plasma sourced from a small draw of peripheral blood. Aurix comprises a natural, endogenous complement of protein and non-protein signal molecules that contribute to effective healing.